Trandolapril / verapamil SR combination reverses drug-induced new-onset diabetes.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D007211:Indoles / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects*; D016896:Treatment Outcome; D014700:Verapamil / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001786:Blood Glucose; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D007211:Indoles; D049993:Sodium Chloride Symporter Inhibitors; C052035:trandolapril; D014700:Verapamil